Johnson & Johnson (JNJ) Income from Continuing Operations (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Income from Continuing Operations came in at 5235000000.0 in Q1 2026, down 52.4% year-on-year from 10999000000.0 in Q1 2025, and up 2.33% quarter-over-quarter from 5116000000.0 in Q4 2025.
Johnson & Johnson (JNJ) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Income from Continuing Operations across 18 years of filings, most recently posting 5235000000.0 for Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 5235000000.0, down 52.4% year-over-year; the trailing twelve-month figure through Mar 2026 was 21040000000.0 (down 3.53% YoY), and the FY2025 annual result was 26804000000.0, up 90.56% from the prior year.
- Income from Continuing Operations came in at 5235000000.0 for Q1 2026 at Johnson & Johnson, up from 5116000000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 10999000000.0 in Q1 2025 to a low of 491000000.0 in Q2 2023.
- The 5-year median for Income from Continuing Operations is 4310000000.0 (2022), against an average of 4411647058.82.
- Across the five-year window, Income from Continuing Operations tumbled 110.94% in 2023 and surged 762.93% in 2024, its largest moves.
- Johnson & Johnson's Income from Continuing Operations stood at 4310000000.0 in 2022, then retreated by 4.13% to 4132000000.0 in 2023, then decreased by 16.97% to 3431000000.0 in 2024, then jumped by 49.11% to 5116000000.0 in 2025, then grew by 2.33% to 5235000000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 5235000000.0 (Q1 2026), 5116000000.0 (Q4 2025), and 5152000000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 3.30 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 5.24 Bn |
| Dec 28, 2025 | 5.12 Bn |
| Sep 28, 2025 | 5.15 Bn |
| Jun 29, 2025 | 5.54 Bn |
| Mar 30, 2025 | 11.00 Bn |
| Dec 29, 2024 | 3.43 Bn |
| Sep 29, 2024 | 2.69 Bn |
| Jun 30, 2024 | 4.69 Bn |
| Mar 31, 2024 | 3.26 Bn |
| Dec 31, 2023 | 4.13 Bn |
| Oct 1, 2023 | 4.31 Bn |
| Jul 2, 2023 | 5.38 Bn |
| Apr 2, 2023 | -491.00 Mn |
| Jan 1, 2023 | 2.65 Bn |
| Oct 2, 2022 | 4.31 Bn |
| Jul 3, 2022 | 4.12 Bn |
| Apr 3, 2022 | 4.49 Bn |
| Oct 3, 2021 | 3.67 Bn |
| Jul 4, 2021 | 6.28 Bn |
| Apr 4, 2021 | 6.20 Bn |